Patents Assigned to XOMA
  • Methods and materials for expression of a recombinant protein
    Publication number: 20060121604
    Abstract: Recombinant expression vectors are provided comprising a 3? UTR of a light chain and an Epstein-Barr virus origin of replication. Also provided are host cells comprising such vectors and methods of producing recombinant protein with such vectors. Additional methods of producing a recombinant protein involve contacting cells with a first and second vector, each of which encode a different polypeptide chain, and wherein the second vector is present in an amount which is about 1.5 to 2.5 times as much as that of the first vector. Cells also can be transfected with a recombinant transient expression vector encoding a protein and are cultured in a medium in a membrane-enhanced culturing vessel to produce recombinant protein.
    Type: Application
    Filed: December 5, 2005
    Publication date: June 8, 2006
    Applicant: XOMA Technology Ltd.
    Inventors: Masahisa Handa, Arnold Horwitz, Eddie Bautista, Robyn Cotter
  • Method of treating chronic cardiac disease
    Patent number: 7045501
    Abstract: New therapeutic uses for BPI protein products that involve treatment of chronic cardiac disease.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: May 16, 2006
    Assignee: XOMA Technology
    Inventors: Brett P. Giroir, Patrick J. Scannon
  • Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
    Patent number: 7045500
    Abstract: The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: May 16, 2006
    Assignee: Xoma Technology Ltd.
    Inventor: Roger G. Little, II
  • Therapeutic uses of BPI protein products in BPI-deficient humans
    Patent number: 7041644
    Abstract: New therapeutic uses for BPI protein products that involve treatment of subjects with a BPI deficiency condition, including selective BPI deficiency, and newborns, including BPI-deficient newborns.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: May 9, 2006
    Assignee: XOMA Technology
    Inventor: Ofer Levy
  • Therapeutic peptide-based constructs derived from Domain II of bactericidal/permeability-increasing protein
    Patent number: 6964948
    Abstract: The present invention relates generally to small peptide-based constructs, including derivatized constructs, and their therapeutic uses. The constructs and derivatized constructs can have at least one of heparin binding, heparin neutralizing, endothelial cell proliferation inhibiting, antiangiogenic, LPS binding, LPS neutralization, or antimicrobial properties. The sequences of these constructs are based on a reverse subsequence derived from Domain II of bactericidal/permeability-increasing protein (BPI).
    Type: Grant
    Filed: July 30, 2002
    Date of Patent: November 15, 2005
    Assignee: Xoma Technology Ltd.
    Inventors: Roger G. Little, II, Jong-Jye Lin, J. G. Kinyua Gikonyo
  • Therapeutic peptide-based constructs
    Patent number: 6906037
    Abstract: The present invention relates generally to small peptide-based constructs and their therapeutic uses. The sequences of these peptide-based constructs are based on a reverse subsequence derived from Domain II of bactericidal/permeability-increasing protein (BPI).
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: June 14, 2005
    Assignee: Xoma Technology Ltd.
    Inventors: Roger G. Little, II, Jong-Jye Lin
  • Treatment of Mycobacterial diseases by administration of bacterial/permeability-increasing protein products
    Publication number: 20050118112
    Abstract: The present invention relates to methods for treating a subject suffering from infection with Mycobacteria, such as M. leprae or M. tuberculosis comprising administering to the subject a composition comprising a bactericidal/permeability-inducing (BPI) protein product alone or in combination with administration of an anti-Mycobacterial antibiotic.
    Type: Application
    Filed: September 8, 2003
    Publication date: June 2, 2005
    Applicant: XOMA CORPORATION
    Inventor: Lewis Lambert
  • Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
    Patent number: 6849598
    Abstract: Improved therapeutic compositions having enhanced anti-microbial activity comprising a bactericidal/permeability-increasing (BPI) protein product and an bactericidal-activity enhancing polyoxyethylene block copolymer surfactant (poloxamer) surfactant or a bacterial and fungal growth-inhibiting enhancing poloaxamer surfactant, optionally with EDTA, and methods for treating bacterial infection by administering such compositions, alone or concurrently with antibiotics.
    Type: Grant
    Filed: October 24, 2000
    Date of Patent: February 1, 2005
    Assignee: XOMA
    Inventor: Lewis H. Lambert, Jr.
  • Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
    Patent number: 6828418
    Abstract: Disclosed are novel bactericidal/permeability-increasing (BPI) protein products wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. Also disclosed are DNA sequences encoding methods for the production of the same in appropriate host cells, and stable homogeneous pharmaceutical compositions containing the analogs suitable for use treatment of gram negative bacterial infection and its sequelae.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: December 7, 2004
    Assignee: Xoma Corporation
    Inventors: Georgia Theofan, Arnold Horwitz, David Burke, Manik Baltaian, Lynn Grinna
  • Methods and cells for expression of recombinant protein products under the transcriptional control of an inducible promoter
    Patent number: 6803210
    Abstract: The present invention relates generally to improved methods for the expression of recombinant protein products under the transcriptional control of an inducible promoter, such as an araB promoter, in bacterial host cells that are deficient in one or more of the active transport systems for the inducer of the inducible promoter. The present invention also relates to improved bacterial host cells that are deficient in one or more of the active transport systems for an inducer of an inducible promoter, such as arabinose for an araB promoter, and contain an expression vector encoding a recombinant polypeptide under the transcriptional control of the inducible promoter, such as an araB promoter.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: October 12, 2004
    Assignee: XOMA Technology Ltd.
    Inventor: Marc D. Better
  • Method of treating conditions associated with intestinal ischemia/reperfusion
    Patent number: 6767893
    Abstract: The present invention provides methods of treating adverse physiological effects associated with intestinal ischemia/reperfusion by administering to a subject suffering from the effects of intestinal ischemia/reperfusion an effective amount of a BPI protein product.
    Type: Grant
    Filed: October 12, 1999
    Date of Patent: July 27, 2004
    Assignee: Xoma Corporation
    Inventors: William Steve Ammons, Károly M. Mészäros
  • Method for quantifying BPI in body fluids
    Patent number: 6759203
    Abstract: The present invention provides a method for quantifying the presence of extracellular BPI in body fluids including blood in a subject comprising conducting a BPI immunoassay on body fluid sample obtained from said subject.
    Type: Grant
    Filed: October 9, 1998
    Date of Patent: July 6, 2004
    Assignee: XOMA Corporation
    Inventors: Mark Leslie White, Stephen Fitzhugh Carroll, Jeremy Kam-kuen Ma
  • Treatment of LFA-1 associated disorders with increasing doses
    Publication number: 20040047859
    Abstract: A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.
    Type: Application
    Filed: September 5, 2003
    Publication date: March 11, 2004
    Applicants: Genentech, Inc., Xoma Ltd.
    Inventors: Marvin R. Garovoy, Susan M. Kramer, Russell L. Dedrick, Karen Starko
  • Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
    Publication number: 20040023884
    Abstract: The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.
    Type: Application
    Filed: May 27, 2003
    Publication date: February 5, 2004
    Applicant: XOMA Corporation
    Inventor: Roger G. Little
  • Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
    Publication number: 20040024179
    Abstract: The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.
    Type: Application
    Filed: December 13, 2002
    Publication date: February 5, 2004
    Applicant: XOMA Technology Ltd.
    Inventor: Roger G. Little
  • Method of treating depressed reticuloendothelial system function
    Patent number: 6686332
    Abstract: The present invention provides methods of treating adverse physiological effects associated with depressed reticuloendothelial system function comprising administering to a subject suffering from depressed reticuloendothelial system function an effective amount of a BPI protein product.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: February 3, 2004
    Assignee: Xoma Corporation
    Inventors: Paul A. M. van Leeuwan, Marja A. Boermeester
  • Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
    Publication number: 20040005630
    Abstract: Methods are described for identifying the amino acid residues of an antibody variable domain which may be modified without diminishing the native affinity of the domain for antigen while reducing its immunogenicity with respect to a hereterologous species and for preparing so modified antibody variable domains which are useful for administration to heterologous species. Antibody variable regions prepared by the methods of the invention are also described.
    Type: Application
    Filed: December 18, 2002
    Publication date: January 8, 2004
    Applicant: XOMA Technology Ltd.
    Inventor: Gary M. Studnicka
  • Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
    Publication number: 20040002452
    Abstract: Improved therapeutic uses for N-terminal BPI protein products are described in patients that have BPI-reactive anti-neutrophil cytoplasmic antibodies.
    Type: Application
    Filed: November 19, 2002
    Publication date: January 1, 2004
    Applicant: XOMA Technology Ltd.
    Inventor: Stephen Fitzhugh Carroll
  • Therapeutic uses of BPI protein products in humans with otitis media with effusion
    Patent number: 6670327
    Abstract: New therapeutic uses for BPI protein products for treating otitis media with effusion in humans are provided.
    Type: Grant
    Filed: June 5, 2000
    Date of Patent: December 30, 2003
    Assignee: Xoma (US) LLC
    Inventors: Jan J. Grote, Maartje J. Nell
  • Uses of lipopolysaccharide binding protein
    Publication number: 20030236187
    Abstract: Novel LBP compositions and therapeutic uses for LBP are provided for preventing the adverse effects of exposure to endotoxin.
    Type: Application
    Filed: October 23, 2001
    Publication date: December 25, 2003
    Applicant: XOMA Corporation
    Inventors: Russell L. Dedrick, Stephen F. Carroll